Southwest Research Institute

Larry Allen Cabell

Joseph A McDonough

Hong Dixon

Stephen Thomas Wellinghoff

Albert M Zwiener

Kenneth Carson

Richard Michael Corbett

Paul M Thompson

Patricia Underwood

Norma L Cantu

Maria Lucy Kimmel

Sandra J Drabik

Andrew P-z Clark

Joseph A Mcdonough

The present invention is directed at aqueous suspensions of oxime compounds, such as 2-pyridine aldoxime methyl chloride (2-PAM Cl) for autoinjectors. The suspensions are able to provide 600 mg of 2-PAM Cl in one relatively small dose of less than or equal to 1.0 mL, and are particularly useful for placement in relatively small size autoinjectors.

Aqueous suspensions of oximes for autoinjectors

Methods for preparing suspensions of active pharmaceutical ingredients for ensuing drug delivery. The suspension may include a mixture of a relatively low dosage API and a relatively high dosage API or a mixture of an API with a suitable excipient.

Dosage suspensions of active pharmaceutical ingredients

The present invention is directed at isoamyl nitrite formulations suitable for use in medicinal applications. The formulations include a composition of isoamyl nitrite in combination with an epoxidized vegetable oil, identified as stabilized isoamyl nitrite. The isoamyl nitrite may also be combined with petrolatum. Methods of treatment of the formulations are applicable to cyanide poisoning, HS poisoning as well as treatment for elevated blood pressure.

Isoamyl nitrite formulations

The present disclosure relates to compositions and methods for producing nanoparticles to provide relatively more rapid delivery of such particles across the blood-brain barrier. The nanoparticles may be formed from bis-quaternary pyridinium-aldoxime salts that may also be of a specific polymorphic structure and which may be formed in either hydrophobic or hydrophilic type liquid media. In addition, the nanoparticle for transport across the blood-brain barrier may comprise a polymeric resin encapsulating a bis-quaternary pyridinium-2-aldoxime salt.

Nanoparticles for drug delivery to the central nervous system

The present invention relates to two phase systems of a bioactive ingredient in particle form that has limited or no solubility in a liquid medium, which provides stability to the bioactive ingredient that is similar to the bioactive ingredient when in the solid state. The bioactive ingredient may be capable of therapeutically treating for the presence of a cholinesterase inhibitor. The bio active ingredient comprises 1,1'-methlyenebis[4-[(hydroxyimino)methyl]-pyridinium]dimethanesulfonate.

Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts

Bis-quaternary pyridinium-aldoxime salts are disclosed, and their associated polymorphic character, along with their methods of preparation. Such polymorphic salts may then be used for treatment of exposure to cholinesterase inhibitors, such as a phosphorous containing cholinesterase inhibitor type compound.

Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors

The present disclosure relates to non-aggregating nanoparticles and their associated methods of preparation. The nanoparticles may have a surface and a size range of 1 nm to 999 nm, along with a zeta potential of &#x2212;50 to 50 millivolts. A polycation and/or polyanion may be disposed on the nanoparticle surface. In addition, an active ingredient may be encapsulated within the nanoparticles or associated with the polycation or polyanion on the nanoparticle surface.

Growing community of inventors

San Antonio, TX, United States of America

Larry Allen Cabell